The United States National Institutes of Health (NIH) is committed to setting research priorities that advance progress toward viral hepatitis elimination. In 2020, Dr. Harvey Alter, NIH researcher, was awarded the Nobel Prize in Medicine and Physiology for his contributions to the discovery of HCV, exemplifying the importance of NIH to hepatitis elimination efforts.
NIH and the Coalition for Global Hepatitis Elimination are launching a new webinar series, "Moving from Hepatitis Discovery to Elimination" to highlight ongoing research that can benefit elimination efforts, support translation of research into implementation, and identify additional research needs.
Fourth Webinar: July 8th, 3-5 pm ET
Improving Early Detection of Hepatocellular Carcinoma (HCC): The Quest for New Biomarkers
Hosted by the National Cancer Institute
Current guidelines (e.g. AASLD) recommend biannual (every 6 months) surveillance for hepatocellular carcinoma (HCC), usually using ultrasound (US) which may or may not include measuring the marker, AFP (alpha-fetoprotein). This is recommended for certain chronic liver diseases (e.g. HBV infected individuals) and also for individuals with cirrhosis. These surveillance recommendations achieve mixed results in their effectiveness for early detection of HCC. There is an unmet need to identify and implement more effective surveillance (e.g. imaging and biomarkers) for the early detection of HCC. This webinar will explore the challenges and opportunities for improving HCC surveillance.
Global Dimension of HCC and Epidemiology- Katherine McGlynn, National Cancer Institute (NCI)
HCC Surveillance Current Practices- Amit Singal, UT Southwestern Medical Center
Biomarkers for HCC- Anand Mehta, Medical University of South Carolina
Risk Assessment of HCC- Nabihah Tayob, Dana-Farber Cancer Institute and Harvard Medical School
Basic HCC Research: Mouse Models- Ray Chung, Massachusetts General Hospital